ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Financial Statements and Exhibits
Item9.01.
| Financial Statements and Exhibits. |
(b)
Pro Forma Financial Information
The unaudited pro forma combined condensed consolidated statement
of operations for the year ended December 31, 2016, together with
related explanatory notes, showing the pro forma effect on the
Companys financial statements of the Companys acquisition of USC
and other related pro forma events, is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
(d)
Exhibits
| 99.1 |
Pro Forma Combined Condensed Consolidated Statement of Operations listed in Item 9.01(b) |
About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology. ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Recent Trading Information
ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) closed its last trading session down -0.10 at 4.40 with 115,505 shares trading hands.
